Diagnostics
3 Early-Stage Non-Invasive Diagnostics Startups Detecting Health Risks Earlier
DealBio tracks early-stage non-invasive diagnostics startups across Europe and North America. These 3 use familiar clinical signals — ECGs, retinal images and heart sounds — to identify people who may need further investigation earlier.
- Non-Invasive Diagnostics
- Clinical AI
- Cardiovascular
- Medical Imaging
- Alzheimer’s disease
Non-invasive diagnostics
Across this group, clinical AI is being applied to different signal types, but the shared thesis is the same: improve risk stratification before a definitive diagnosis is made. That puts workflow fit and prospective clinical validation alongside model performance as central questions for investors.clinical AIrisk stratification
At a Glance
- Cardiovolt.aiUnited Kingdom2025AI analysis of routine ECGs
- Cambridge Vision TechnologyUnited Kingdom2023Retinal imaging for Alzheimer’s risk screening
- AuscultaNetSwitzerland2026AI-assisted heart-valve screening from stethoscope recordings
Developing AI software to detect and predict heart disease from ECGs.
- Country
United Kingdom- Founded
- 2025
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
Why Cardiovolt.ai stands out
Cardiovolt.ai is commercializing AI-ECG research with £1.4 million in funding reported by Imperial College London, with Twin Path Ventures leading the pre-seed backing. Its AIRE model was developed on more than 1.16 million ECGs and externally tested across five cohorts for mortality-risk ranking.
The startup has also validated models for future heart-valve disease risk, while the founding team combines cardiovascular research, clinical cardiology and AI development. Several founders’ work has been supported by the British Heart Foundation.
What Cardiovolt.ai is building
Cardiovolt.ai analyzes routine 12-lead ECG recordings using neural networks trained on linked patient outcomes. Separate models are designed to detect existing disease and estimate future risk, turning a standard recording into an additional risk-stratification layer.
The software accepts digital ECG waveforms or images from standard clinical recordings. Its intended role is to help clinicians prioritize further investigation and follow-up, while confirmatory imaging remains part of the care pathway.
Developing retinal imaging and AI for early Alzheimer’s risk screening.
- Country
- United Kingdom
- Founded
- 2023
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
Why Cambridge Vision Technology stands out
Cambridge Vision Technology secured a UK public-sector development contract through Innovate UK’s SBRI programme for dementia biomarker tools. It also entered Cambridge Enterprise’s life-sciences portfolio after completing the University of Cambridge START 1.0 accelerator.
Co-founder James Wood previously built an electronic clinical-referral system that handled more than 200,000 patient transfers for the NHS, adding direct experience with the routing problem that screening products ultimately need to solve.
What Cambridge Vision Technology is building
A-Eye Scope combines retinal-imaging hardware with software that analyzes vascular features in the retina alongside inputs such as cognitive-test results. The system is intended to support Alzheimer’s risk stratification before specialist assessment.
The team is developing a non-invasive retinal-imaging headset with automated capture and an integrated platform for image storage and analysis. The intended role is to identify people who may need further dementia assessment rather than replace definitive diagnostic pathways.
Turning stethoscope recordings into AI-assisted heart valve screening.
- Country
Switzerland- Founded
- 2026
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why AuscultaNet stands out
AuscultaNet reached 91.7% AUROC on held-out benchmark data, with 82.2% sensitivity and 84.1% specificity in company-run testing using public heart-sound data. It was also named a 2026 >>venture>> Medtech & Healthcare semifinalist.
The startup joined SITEM’s MedTech Booster in January 2026, adding regulatory mentoring and access to a hospital-focused startup network as it prepares prospective validation against echocardiography.
What AuscultaNet is building
AuscultaNet processes digital stethoscope recordings from four standard cardiac listening sites. Its offline AI detects murmurs, classifies their timing, estimates grade and returns a prioritized recommendation.
The product is designed to support referral decisions in primary care, including when echocardiography should be considered. By working with digital stethoscope recordings, it adds an analysis layer to a familiar examination rather than requiring a new imaging system.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
The investment pattern across these startups is less about replacing established diagnostics than improving the step before them. Cardiovolt.ai aims to extract hidden risk from an ECG, Cambridge Vision Technology uses the retina as an accessible screening surface, and AuscultaNet adds structured AI interpretation to cardiac auscultation. In each case, the product becomes commercially useful when an earlier signal leads to a clear next action.
That makes clinical workflow and evidence quality especially important. Retrospective or benchmark performance can establish technical promise, but the next value-creating proof is whether the tool works prospectively across real users and sites and improves referral or follow-up decisions without creating unnecessary downstream testing. Startups that can demonstrate that transition may build defensibility around integration and clinical utility, not only around the underlying model.
Methodology
DealBio selected these three early-stage startups because each uses a non-invasive clinical signal to identify health risks earlier and guide further assessment. The selection spans routine ECGs, retinal imaging and digital auscultation, with a shared focus on risk stratification before confirmatory testing or specialist review.retinal imagingdigital auscultation
DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.